메뉴 건너뛰기




Volumn 14, Issue 8, 2011, Pages 1039-1047

Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease

Author keywords

chronic obstructive pulmonary disease; exacerbations; model; probabilistic; progression

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MODEL; MORTALITY; POPULATION DYNAMICS; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SMOKING CESSATION; STOCHASTIC MODEL;

EID: 82955205825     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.06.008     Document Type: Article
Times cited : (31)

References (56)
  • 2
    • 32644435902 scopus 로고    scopus 로고
    • COPD exacerbations 1: Epidemiology
    • G.C. Donaldson, J.A. Wedzicha COPD exacerbations 1: Epidemiology Thorax 61 2006 164 168
    • (2006) Thorax , vol.61 , pp. 164-168
    • Donaldson, G.C.1    Wedzicha, J.A.2
  • 3
    • 33646352211 scopus 로고    scopus 로고
    • Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations
    • DOI 10.1513/pats.200510-107SF
    • J. Vestbo Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations Proc Am Thorac Soc 3 2006 252 256 (Pubitemid 43668190)
    • (2006) Proceedings of the American Thoracic Society , vol.3 , Issue.3 , pp. 252-256
    • Vestbo, J.1
  • 4
    • 24644439190 scopus 로고    scopus 로고
    • Trends in the leading causes of death in the United States, 1970-2002
    • DOI 10.1001/jama.294.10.1255
    • A. Jemal, E. Ward, Y. Hao et al. Trends in the leading causes of death in the United States, 1970-2002 JAMA 294 2005 1255 1259 (Pubitemid 41352114)
    • (2005) Journal of the American Medical Association , vol.294 , Issue.10 , pp. 1255-1259
    • Jemal, A.1    Ward, E.2    Hao, Y.3    Thun, M.4
  • 5
    • 0031001720 scopus 로고    scopus 로고
    • Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
    • DOI 10.1016/S0140-6736(96)07492-2
    • C.J. Murray, A.D. Lopez Alternative projections of mortality and disability by cause 19902020: Global Burden of Disease Study Lancet 349 1997 1498 1504 (Pubitemid 27216360)
    • (1997) Lancet , vol.349 , Issue.9064 , pp. 1498-1504
    • Murray, C.J.L.1    Lopez, A.D.2
  • 6
    • 1842457093 scopus 로고    scopus 로고
    • A Computer Simulation Model of the Natural History and Economic Impact of Chronic Obstructive Pulmonary Disease
    • DOI 10.1111/j.1524-4733.2004.72318.x
    • S. Borg, A. Ericsson, J. Wedzicha et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease Value Health 7 2004 153 167 (Pubitemid 38420728)
    • (2004) Value in Health , vol.7 , Issue.2 , pp. 153-167
    • Borg, S.1    Ericsson, A.2    Wedzicha, J.3    Gulsvik, A.4    Lundback, B.5    Donaldson, G.C.6    Sullivan, S.D.7
  • 7
    • 1242315575 scopus 로고    scopus 로고
    • Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity
    • DOI 10.1016/j.amjmed.2003.09.027
    • D.D. Sin, K. Golmohammadi, P. Jacobs Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity Am J Med 116 2004 325 331 (Pubitemid 38230292)
    • (2004) American Journal of Medicine , vol.116 , Issue.5 , pp. 325-331
    • Sin, D.D.1    Golmohammadi, K.2    Jacobs, P.3
  • 8
    • 22244479358 scopus 로고    scopus 로고
    • Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease
    • DOI 10.2165/00019053-200523060-00008
    • M. Spencer, A.H. Briggs, R.F. Grossman et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease Pharmacoeconomics 23 2005 619 637 (Pubitemid 40994129)
    • (2005) PharmacoEconomics , vol.23 , Issue.6 , pp. 619-637
    • Spencer, M.1    Briggs, A.H.2    Grossman, R.F.3    Rance, L.4
  • 10
    • 14344257828 scopus 로고    scopus 로고
    • Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries
    • DOI 10.1111/j.1524-4733.2005.03086.x
    • J.B. Oostenbrink, M.P. Rutten-van Molken, B.U. Monz et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries Value Health 8 2005 32 46 (Pubitemid 40293639)
    • (2005) Value in Health , vol.8 , Issue.1 , pp. 32-46
    • Oostenbrink, J.B.1    Rutten-Van Molken, M.P.M.H.2    Monz, B.U.3    FitzGerald, J.M.4
  • 11
    • 34547617931 scopus 로고    scopus 로고
    • Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients
    • N.R. Dal, M. Eandi, L. Pradelli et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients Int J Chron Obstruct Pulmon Dis 2 2007 169 176 (Pubitemid 47202217)
    • (2007) International Journal of COPD , vol.2 , Issue.2 , pp. 169-176
    • Dal Negro, R.1    Eandi, M.2    Pradelli, L.3    Iannazzo, S.4
  • 12
    • 60749089756 scopus 로고    scopus 로고
    • Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease
    • A. Chuck, P. Jacobs, I. Mayers et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease Can Respir J 15 2008 437 443
    • (2008) Can Respir J , vol.15 , pp. 437-443
    • Chuck, A.1    Jacobs, P.2    Mayers, I.3
  • 13
    • 70349646763 scopus 로고    scopus 로고
    • Present and future costs of COPD in Iceland and Norway: Results from the BOLD study
    • R. Nielsen, A. Johannessen, B. Benediktsdottir et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study Eur Respir J 34 2009 850 857
    • (2009) Eur Respir J , vol.34 , pp. 850-857
    • Nielsen, R.1    Johannessen, A.2    Benediktsdottir, B.3
  • 14
    • 58049090292 scopus 로고    scopus 로고
    • Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD
    • S.R. Earnshaw, M.R. Wilson, A.A. Dalal et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD Respir Med 103 2009 12 21
    • (2009) Respir Med , vol.103 , pp. 12-21
    • Earnshaw, S.R.1    Wilson, M.R.2    Dalal, A.A.3
  • 15
    • 33748806056 scopus 로고    scopus 로고
    • Economic modeling in chronic obstructive pulmonary disease
    • DOI 10.1513/pats.200603-095SS
    • M. Rutten-van Molken, T.A. Lee Economic modeling in chronic obstructive pulmonary disease Proc Am Thorac Soc 3 2006 630 634 (Pubitemid 44411632)
    • (2006) Proceedings of the American Thoracic Society , vol.3 , Issue.7 , pp. 630-634
    • Molken, M.R.-V.1    Lee, T.A.2
  • 16
    • 0034086702 scopus 로고    scopus 로고
    • Handling uncertainty in cost-effectiveness models
    • A.H. Briggs Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 2000 479 500 (Pubitemid 30398806)
    • (2000) PharmacoEconomics , vol.17 , Issue.5 , pp. 479-500
    • Briggs, A.H.1
  • 18
    • 77956031239 scopus 로고    scopus 로고
    • Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD
    • M. Hoogendoorn, T.L. Feenstra, R.T. Hoogenveen et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD Thorax 65 2010 711 718
    • (2010) Thorax , vol.65 , pp. 711-718
    • Hoogendoorn, M.1    Feenstra, T.L.2    Hoogenveen, R.T.3
  • 19
    • 82955247237 scopus 로고    scopus 로고
    • Meta-analysis of FEV1 as a risk factor for all-cause mortality
    • M.P.M.H. Rutten-van Molken, R.T. Hoogenveen, T.L. Feenstra et al. Meta-analysis of FEV1 as a risk factor for all-cause mortality Eur Respir J 22 Suppl. 45 2003 P3047
    • (2003) Eur Respir J , vol.22 , Issue.SUPPL. 45 , pp. 3047
    • Rutten-Van Molken, M.P.M.H.1    Hoogenveen, R.T.2    Feenstra, T.L.3
  • 22
    • 34250644441 scopus 로고    scopus 로고
    • Health status impairment and costs associated with COPD exacerbation managed in hospital
    • DOI 10.1111/j.1742-1241.2007.01424.x
    • J.F. O'Reilly, A.E. Williams, L. Rice Health status impairment and costs associated with COPD exacerbation managed in hospital Int J Clin Pract 61 2007 1112 1120 (Pubitemid 46934632)
    • (2007) International Journal of Clinical Practice , vol.61 , Issue.7 , pp. 1112-1120
    • O'Reilly, J.F.1    Williams, A.E.2    Rice, L.3
  • 26
    • 41049097488 scopus 로고    scopus 로고
    • Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation
    • R.T. Hoogenveen, P.H. van Baal, H.C. Boshuizen et al. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation Cost Eff Resour Alloc 6 2008 1
    • (2008) Cost Eff Resour Alloc , vol.6 , pp. 1
    • Hoogenveen, R.T.1    Van Baal, P.H.2    Boshuizen, H.C.3
  • 29
    • 0003649181 scopus 로고
    • US Department of Health and Human Services Hyattsville, MD DHHS Publication No. (CDC) 90-8416
    • The Health Benefits of Smoking Cessation 1990 US Department of Health and Human Services Hyattsville, MD DHHS Publication No. (CDC) 90-8416
    • (1990) The Health Benefits of Smoking Cessation
  • 30
    • 26044441678 scopus 로고    scopus 로고
    • Volksgezondheid Toekomst Verkenning City, Country
    • J.A.M. van Oers Gezondheid op koers? 2002 Volksgezondheid Toekomst Verkenning City, Country
    • (2002) Gezondheid Op Koers?
    • Van Oers, J.A.M.1
  • 32
    • 0027962628 scopus 로고
    • Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 the Lung Health Study
    • N.R. Anthonisen, J.E. Connett, J.P. Kiley et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 The Lung Health Study JAMA 272 1994 1497 1505
    • (1994) JAMA , vol.272 , pp. 1497-1505
    • Anthonisen, N.R.1    Connett, J.E.2    Kiley, J.P.3
  • 34
    • 82955168570 scopus 로고    scopus 로고
    • Statistic Netherlands The Hague, Netherlands
    • All-cause mortality 2006 Statistic Netherlands The Hague, Netherlands
    • (2006) All-cause Mortality
  • 36
    • 79960383347 scopus 로고    scopus 로고
    • Statistic Netherlands The Hague, Netherlands
    • Consumer Price Indices 2008 Statistic Netherlands The Hague, Netherlands
    • (2008) Consumer Price Indices
  • 38
    • 79952200871 scopus 로고    scopus 로고
    • Association between lung function and exacerbation frequency in patients with COPD
    • M. Hoogendoorn, T.L. Feenstra, R.T. Hoogenveen et al. Association between lung function and exacerbation frequency in patients with COPD Int J Chron Obstruct Pulmon Dis 5 2010 435 444
    • (2010) Int J Chron Obstruct Pulmon Dis , vol.5 , pp. 435-444
    • Hoogendoorn, M.1    Feenstra, T.L.2    Hoogenveen, R.T.3
  • 39
    • 79953674776 scopus 로고    scopus 로고
    • Case-fatality of COPD exacerbations: A meta-analysis and statistical modeling approach
    • M. Hoogendoorn, R.T. Hoogenveen, M.P. Rutten-van Molken et al. Case-fatality of COPD exacerbations: a meta-analysis and statistical modeling approach Eur Respir J 37 2011 508 515
    • (2011) Eur Respir J , vol.37 , pp. 508-515
    • Hoogendoorn, M.1    Hoogenveen, R.T.2    Rutten-Van Molken, M.P.3
  • 40
    • 0036794862 scopus 로고    scopus 로고
    • Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
    • DOI 10.1136/thorax.57.10.847
    • G.C. Donaldson, T.A. Seemungal, A. Bhowmik et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852 (Pubitemid 35178607)
    • (2002) Thorax , vol.57 , Issue.10 , pp. 847-852
    • Donaldson, G.C.1    Seemungal, T.A.R.2    Bhowmik, A.3    Wedzicha, J.A.4
  • 42
    • 0035422691 scopus 로고    scopus 로고
    • 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the Lung Health Study
    • R.E. Kanner, N.R. Anthonisen, J.E. Connett Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study Am J Respir Crit Care Med 164 2001 358 364 (Pubitemid 32778199)
    • (2001) American Journal of Respiratory and Critical Care Medicine , vol.164 , Issue.3 , pp. 358-364
    • Kanner, R.E.1    Anthonisen, N.R.2    Connett, J.E.3
  • 43
    • 2442552129 scopus 로고    scopus 로고
    • Impact of preventing exacerbations on deterioration of health status in COPD
    • DOI 10.1183/09031936.04.00121404
    • S. Spencer, P.M. Calverley, P.S. Burge et al. Impact of preventing exacerbations on deterioration of health status in COPD Eur Respir J 23 2004 698 702 (Pubitemid 38618138)
    • (2004) European Respiratory Journal , vol.23 , Issue.5 , pp. 698-702
    • Spencer, S.1    Calverley, P.M.A.2    Burge, P.S.3    Jones, P.W.4
  • 44
    • 48949103222 scopus 로고    scopus 로고
    • Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study
    • B.R. Celli, N.E. Thomas, J.A. Anderson et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
    • (2008) Am J Respir Crit Care Med , vol.178 , pp. 332-338
    • Celli, B.R.1    Thomas, N.E.2    Anderson, J.A.3
  • 45
    • 4043134574 scopus 로고    scopus 로고
    • Resource use and risk factors in high-cost exacerbations of COPD
    • DOI 10.1016/j.rmed.2004.02.013, PII S0954611104000824
    • J.B. Oostenbrink, M.P. Rutten-van Molken Resource use and risk factors in high-cost exacerbations of COPD Respir Med 98 2004 883 891 (Pubitemid 39069339)
    • (2004) Respiratory Medicine , vol.98 , Issue.9 , pp. 883-891
    • Oostenbrink, J.B.1    Rutten-Van Molken, M.P.M.H.2
  • 47
    • 75149179709 scopus 로고    scopus 로고
    • Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective?
    • M. Hoogendoorn, C.R. van Wetering, A.M. Schols et al. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 35 2010 79 87
    • (2010) Eur Respir J , vol.35 , pp. 79-87
    • Hoogendoorn, M.1    Van Wetering, C.R.2    Schols, A.M.3
  • 49
    • 0028509556 scopus 로고
    • Costs, effects and C/E-ratios alongside a clinical trial
    • B.A. van Hout, M.J. Al, G.S. Gordon et al. Costs, effects and C/E-ratios alongside a clinical trial Health Econ 3 1994 309 319
    • (1994) Health Econ , vol.3 , pp. 309-319
    • Van Hout, B.A.1    Al, M.J.2    Gordon, G.S.3
  • 50
    • 0035669803 scopus 로고    scopus 로고
    • Representing uncertainty: The role of cost-effectiveness acceptability curves
    • DOI 10.1002/hec.635
    • E. Fenwick, K. Claxton, M. Sculpher Representing uncertainty: the role of cost-effectiveness acceptability curves Health Econ 10 2001 779 787 (Pubitemid 34041389)
    • (2001) Health Economics , vol.10 , Issue.8 , pp. 779-787
    • Fenwick, E.1    Claxton, K.2    Sculpher, M.3
  • 51
    • 2442652725 scopus 로고    scopus 로고
    • Cost-effectiveness acceptability curves - Facts, fallacies and frequently asked questions
    • DOI 10.1002/hec.903
    • E. Fenwick, B.J. O'Brien, A. Briggs Cost-effectiveness acceptability curvesfacts, fallacies and frequently asked questions Health Econ 13 2004 405 415 (Pubitemid 38660390)
    • (2004) Health Economics , vol.13 , Issue.5 , pp. 405-415
    • Fenwick, E.1    O'Brien, B.J.2    Briggs, A.3
  • 52
    • 28844508639 scopus 로고    scopus 로고
    • Smoking cessation in patients with COPD in daily general practice (SMOCC): Six months' results
    • DOI 10.1016/j.ypmed.2005.08.003, PII S0091743505001180
    • S.R. Hilberink, J.E. Jacobs, B.J. Bottema et al. Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results Prev Med 41 2005 822 827 (Pubitemid 41772657)
    • (2005) Preventive Medicine , vol.41 , Issue.5-6 , pp. 822-827
    • Hilberink, S.R.1    Jacobs, J.E.2    Bottema, B.J.A.M.3    De Vries, H.4    Grol, R.P.T.M.5
  • 54
    • 72549113283 scopus 로고    scopus 로고
    • Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: The DOSE Index
    • R.C. Jones, G.C. Donaldson, N.H. Chavannes et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index Am J Respir Crit Care Med 180 2009 1189 1195
    • (2009) Am J Respir Crit Care Med , vol.180 , pp. 1189-1195
    • Jones, R.C.1    Donaldson, G.C.2    Chavannes, N.H.3
  • 55
    • 69149083159 scopus 로고    scopus 로고
    • Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index
    • M.A. Puhan, J. Garcia-Aymerich, M. Frey et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index Lancet 374 2009 704 711
    • (2009) Lancet , vol.374 , pp. 704-711
    • Puhan, M.A.1    Garcia-Aymerich, J.2    Frey, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.